Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC

Exclusion Criteria

• •1. Pregnant or breast-feeding women, or women of childbearing potential unless effective methods of contraception are used
• •2. Previous systemic chemotherapy or biological therapy within 21 days of commencing atovaquone treatment
• •3. Treatment with any other investigational agent as part of a clinical trial within 28 days of study enrolment
• •4. Previous thoracic radiotherapy
• •5. Known previous adverse reaction to atovaquone or its excipients
• •6. Active hepatitis, gallbladder disease or pancreatitis
• •7. Impaired gastrointestinal function that may significantly alter absorption of atovaquone
• •8. Concurrent administration of warfarin in the 14 days prior to starting atovaquone
• •9. Concurrent administration of known electron transport chain inhibitors (e.g. metformin). A wash-out period prior to administration of atovaquone is required (e.g. 4 days for metformin).
• •10. An additional cancer diagnosis that the treating clinician feels may significantly impact planned CRT treatment tolerability or treatment outcome
• •11. Established diagnosis of pulmonary fibrosis
• •12. Established diagnosis of connective tissue disorder (e.g. scleroderma or systemic lupus erythematosus)
• •13. Cardiac morbidity such as angina, myocardial infarction in the previous six months, unstable angina or uncontrolled hypertension, left ventricular failure or severe valvular disease